For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on January 31st, 2023 | 14:48 CET
Energy transition price rockets: American Lithium, Plug Power, Auxico Resources
Are shares related to electromobility among the price rockets of 2023? In any case, the start of the year was promising. After a partially disastrous second half of 2022, many stocks are showing strength in the new year. Lithium shares, in particular, are in demand again. Among the high flyers of recent months is American Lithium. After the Nasdaq listing and the planned spin-off of the uranium division, investors are eagerly awaiting the feasibility study. Will the share price fireworks continue? Analysts also expect such fireworks at Auxico Resources. They believe that the share price of the trader of rare earths and critical raw materials could almost triple. Hydrogen pioneer Plug Power has also bounced back in the new year. But once again, the US company has disappointed operationally. How do investors react?
Read
Commented by Fabian Lorenz on January 26th, 2023 | 20:11 CET
Big surprise for Tesla hunter BYD and JinkoSolar: when will dynaCERT share takeoff?
Now, this would be a real surprise: Will Tesla hunter BYD soon not only sell its e-cars in Germany but also produce them? According to media reports, the Chinese carmaker is talking to Ford about buying the plant in Saarlouis. Another Chinese group is also continuing to go full throttle: JinkoSolar. The solar group reports strong figures, the start of construction of a reference project and analysts increase the price target for the share. Investors are also waiting for a big bang from dynaCERT. The cleantech company wants to enter into trading with emission certificates. In addition, sales figures are increasing in the core business.
Read
Commented by Fabian Lorenz on January 25th, 2023 | 13:54 CET
Bayer shares soon to reach triple digits? Barrick Gold and Desert Gold praised by analysts
Will Bayer be broken up, or will triple-digit share prices beckon? According to media reports, more and more investors are calling for the former. Most recently, Bluebell Capital Partners. According to the Bloomberg news agency, the British investor is calling on the DAX-listed Company to separate its Crop Science and Pharmaceuticals divisions. This could lead to a 70% increase in value for shareholders. Analysts also see considerable share price potential and believe that triple-digit prices are possible. Gold is also shining again. However, this has yet to be realized by exploration companies in particular. Experts see the chance of a revaluation at Desert Gold, for example - through takeover fantasy and drilling results. Besides B2Gold, Barrick Gold also comes into question as a buyer. The industry leader is also recommended as a buy, despite weakening Q4 results.
Read
Commented by Fabian Lorenz on January 19th, 2023 | 11:24 CET
Nel after the ITM Power shock: Better to bet on BioNTech and Alpina Holdings?
The year 2022 was not the year of growth stocks. Will this change in 2023? The positive start to the current year shows that the chances of this happening are quite good; however, not in the hydrogen sector. The renewed warning from ITM Power is weighing on the entire sector and stoking fears that Nel, Plug Power & Co. will not be able to work off their full order books in 2023 either. That is where a look at other sectors and stocks can pay off. Example: Alpina Holdings from Singapore. The Company is growing at double-digit rates, and its valuation is incredibly low. BioNTech wants to expand further. Goldman Sachs expects strong newsflow from the cancer pipeline in 2023.
Read
Commented by Fabian Lorenz on January 17th, 2023 | 16:28 CET
Commodity stocks poised for a comeback? Barrick Gold, American Lithium, Globex Mining, Standard Lithium
Inflation is weakening, and the interest rate cycle is nearing its end. This argues for a comeback of gold mining stocks. In any case, the gold price is already pointing in the right direction. Now heavyweights like Barrick Gold must follow. Explorer shares offer disproportionate opportunities. However, Globex Mining is an interesting alternative for those who shy away from individual risks. With more than 200 investments in the commodity sector, the Canadians are positioned similarly to a fund. Currently, the cash balance alone corresponds to half of the market capitalization. In addition, there is positive news from the projects. The lithium sector is also starting to recover. Companies like Standard Lithium and American Lithium are recovering from the sell-off at the end of the year. In addition, takeover fantasy attracts.
Read
Commented by Fabian Lorenz on January 12th, 2023 | 14:20 CET
Shares ready for takeoff: Nel, Plug Power, BASF, Almonty Industries
The New Year rally is on! The Nel share has gained around 20% since New Year's Eve. There was a tailwind from Federal Minister of Economics Robert Habeck, including a major order from Germany. Analysts see further upside potential. This also applies to BASF. A US analyst sees an opportunity for a good 30% price gain for the chemical giant. BASF should benefit from the current sharp decline in gas prices. The agricultural boom is also playing into the DAX company's hands. Almonty Industries wants to benefit even more from the boom in electric mobility in the future. To this end, the Group intends to become one of the leading tungsten producers. The mega-mine in South Korea is scheduled to go into operation in the current year, 2023. Financing by the German KfW has been secured, and analysts see a share price potential of over 100%.
Read
Commented by Fabian Lorenz on January 4th, 2023 | 07:17 CET
Takeover fever 2023? BioNTech, Barrick Gold, Standard Lithium, Manuka Resources
The pharmaceutical sector was already in takeover fever last year. BioNTech partner Pfizer, among others, made several acquisitions. The hunger for acquisitions is likely to continue in the current year as major pharmaceutical and biotech companies are looking to fill up their pipelines. The current year could also be exciting for gold stocks. In 2022, companies failed to keep pace with the positive gold price. Producers of raw materials for the energy transition could also get into takeover fever. Manuka Resources could benefit from the latest two trends. The Canadians have just carried out a capital measure to advance their projects. Corporations could also target specialists like Standard Lithium. Rumours that Tesla is looking at lithium projects have been doing the rounds for a long time. And what about Barrick Gold and BioNTech?
Read
Commented by Fabian Lorenz on December 28th, 2022 | 08:05 CET
Outperformer stocks in 2023? BioNTech, Steinhoff, Saturn Oil + Gas, K+S
Will energy stocks continue to be outperformers in 2023? In any case, in 2022, MSCI World Energy clearly outperformed MSCI World. In the case of individual stocks, Shell, for example, has gained over 45% in the current year. Jefferies recommends the stock as a buy with a target price of GPX 3100 (pence). Warren Buffett has also invested billions in the oil sector in 2022. Chevron and Occidental Petroleum are among Berkshire Hathaway's seven largest holdings. Energy, after all, is likely to be in demand in 2023. Those looking to bet on a laggard should look at Saturn Oil & Gas. The Canadian oil producer faces a milestone in 2023, and analysts see over 200% upside potential. BioNTech enters the new year with solid newsflow. And what is Steinhoff doing after the horror news?
Read
Commented by Fabian Lorenz on December 27th, 2022 | 06:07 CET
Excitement at BASF, Nel ASA, Meta Materials: Shares for 2023
After a difficult 2022, investors are looking ahead to the coming year. In 2023, it will be important to pick the right stocks again because there will be winners - despite the war in Ukraine, high inflation and rising interest rates. At the same time, the price rockets of the old year are rarely also those of the new year. As is well known, BASF shares have struggled in 2022. If energy prices continue to ease, the high dividend yield, among other things, will entice investors. Also, there is news in the electromobility megamarket. There is no question that hydrogen offers huge opportunities worldwide. But companies like Nel and Plug Power must finally wake up faster and reduce losses. At Nel ASA, a sell recommendation weighed on the share price at the end of the year. Hot stock Meta Materials has already multiplied sales in the first 3 quarters of 2022, and the chances are good that the positive trend will continue in 2023. Then the Meta Materials share should also take off.
Read
Commented by Fabian Lorenz on December 21st, 2022 | 08:48 CET
BASF, BioNTech, Cardiol Therapeutics: Stocks for 2023?
Is there a 400% upside potential in 2023? At the end of a challenging 2022 stock market year, we are looking ahead to the new year. Which share is worth buying, and which is better left alone? In the case of BASF, the high dividend yield is one of the attractions. The latest company news shows that the chemical group is also involved in the mega market of electromobility. But the dependence on gas supplies is causing uncertainty, and an analyst has renewed a sell recommendation for BASF shares. BioNTech, on the other hand, is looking good, even if the chart picture has recently clouded over. The development pipeline is full, capacities - especially in Asia - are being expanded, and analysts are also more courageous again. Investors also need a little courage and, above all, patience with Cardiol Therapeutics. They could soon be rewarded. The cash position of the biotech pearl is almost equal to the market capitalization, the main product is already in the Phase 2 pilot study, and analysts see massive upside potential.
Read